uniQure (NASDAQ:QURE) Stock Price Up 3.9% - Here's Why

Shares of uniQure (NASDAQ:QURE - Get Free Report) traded up 3.9% during trading on Tuesday . The stock traded as high as $9.66 and last traded at $9.53. 71,205 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,676,247 shares. The stock had previously closed at $9.17.

Analyst Ratings Changes

Several brokerages recently issued reports on QURE. StockNews.com upgraded uniQure to a "sell" rating in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research report on Tuesday, March 4th. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. Chardan Capital started coverage on shares of uniQure in a report on Tuesday, April 1st. They issued a "buy" rating and a $38.00 target price on the stock. Finally, Wells Fargo & Company decreased their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, uniQure presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.80.

uniQure Stock Up 38.4 %

The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $703.00 million, a price-to-earnings ratio of -2.62 and a beta of 0.42. The firm has a 50 day moving average price of $11.89 and a two-hundred day moving average price of $11.28.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock worth $961,401 over the last ninety days. 4.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC acquired a new position in uniQure in the 4th quarter worth $38,410,000. Franklin Resources Inc. lifted its stake in shares of uniQure by 33.1% in the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after acquiring an additional 494,726 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares during the last quarter. Integral Health Asset Management LLC grew its stake in uniQure by 175.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $19,426,000 after purchasing an additional 700,000 shares in the last quarter. Finally, RTW Investments LP increased its holdings in uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after purchasing an additional 893,625 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.